<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119262</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02977</org_study_id>
    <secondary_id>NCI-2012-02977</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E2104</secondary_id>
    <secondary_id>E2104</secondary_id>
    <nct_id>NCT00119262</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer</brief_title>
  <official_title>Phase II Feasibility Trial Incorporating Bevacizumab Into Dose Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Patients With Lymph Node Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well giving bevacizumab together with combination
      chemotherapy works in treating patients who have undergone surgery for breast cancer that has
      spread to the lymph nodes. Monoclonal antibodies, such as bevacizumab, can block tumor growth
      in different ways. Some block the ability of tumor cells to grow and spread. Others find
      tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may
      also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in
      chemotherapy work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Giving bevacizumab together with more than one
      chemotherapy drug (combination chemotherapy), may be a better way to block tumor growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the incidence of clinically apparent cardiac dysfunction in patients with
      lymph node positive breast cancer treated with bevacizumab and dose dense
      doxorubicin/cyclophosphamide followed by paclitaxel (ddAC &gt; T).

      SECONDARY OBJECTIVES:

      I. To evaluate changes in LVEF during treatment. II. To evaluate non-cardiac toxicity.

      OUTLINE: This is a non-randomized, multicenter study. Patients are sequentially assigned to 1
      of 2 treatment arms.

      Arm A: Patients receive doxorubicin IV, cyclophosphamide IV over 20-30 minutes, and
      bevacizumab IV over 30-90 minutes on day 1. Patients also receive filgrastim (G-CSF)
      subcutaneously (SQ) on days 2-11 or pegfilgrastim SC on day 2. Treatment repeats every 14
      days for 4 courses. Patients then receive paclitaxel IV over 3 hours and bevacizumab IV over
      30-90 minutes on day 1. Patients also receive G-CSF or pegfilgrastim as above. Treatment with
      paclitaxel, bevacizumab, and G-CSF or pegfilgrastim repeats every 14 days for 4 courses.
      Patients then receive bevacizumab alone every 14 days for up to 18 courses.

      Arm B: Patients receive doxorubicin, cyclophosphamide, and G-CSF or pegfilgrastim as in group
      I. Patients then receive paclitaxel, bevacizumab, and G-CSF or pegfilgrastim as in group I.
      Patients then receive bevacizumab alone every 14 days for up to 22 courses.

      Treatment in both groups continues in the absence of disease recurrence or unacceptable
      toxicity.

      Patients who require radiotherapy (post-lumpectomy) or who plan radiotherapy at the
      discretion of the investigator (post-mastectomy) undergo radiotherapy beginning within 6
      weeks after the completion of chemotherapy.

      Premenopausal patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive
      disease receive oral tamoxifen once daily for 5 years beginning at the time of radiotherapy
      or within 6 weeks after the completion of chemotherapy. Postmenopausal patients with ER
      and/or PR positive disease receive an aromatase inhibitor (e.g., anastrozole, letrozole, or
      exemestane) or tamoxifen followed by an aromatase inhibitor once daily for up to 10 years.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then every 6 months for up to 3 years from study entry.

      ACCRUAL: A total of 226 patients (104 on arm A and 122 on arm B) were accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Congestive Heart Failure Rate</measure>
    <time_frame>assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment, then every 3 months for &lt;2 years and every 6 months for 2-3 years from study entry</time_frame>
    <description>Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN), or symptomatic diastolic dysfunction. 223 treated patients were included in the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Absolute Decrease in Left Ventricular Ejection Fraction (LVEF) Levels Post Doxorubicin and Cyclophosphamide(AC)</measure>
    <time_frame>assessed on day 1 of cycles 5, 9, 17, 25, and at end of treatment</time_frame>
    <description>The endpoint was measured by absolute decrease from baseline in LVEF of &gt;15% or &gt;10% decline from baseline to below the LLN post doxorubicin and cyclophosphamide (AC) Day 1 Cycle 5 (DIC5). 207 patients who were treated and had baseline and DIC5 LVEF values were included in the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With Absolute Decrease in LVEF Levels Post Bevacizumab</measure>
    <time_frame>assessed on day 1 of cycles 5, 9, 17, 25, and at end of treatment</time_frame>
    <description>The endpoint was measured by absolute decrease from baseline in LVEF of &gt;15% or &gt;10% decline from baseline to below the LLN post bevacizumab (the end of treatment). 158 patients who were treated and had baseline and end of treatment LVEF values were included in the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Male Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>Filgrastim SD-01</other_name>
    <other_name>GCSF-SD01</other_name>
    <other_name>Neulasta</other_name>
    <other_name>SD-01 sustained duration G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiation therapy</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>Nolvadex</other_name>
    <other_name>TAM</other_name>
    <other_name>tamoxifen</other_name>
    <other_name>TMX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aromatase inhibition therapy</intervention_name>
    <description>Receive aromatase inhibition therapy</description>
    <arm_group_label>Arm I (combination chemotherapy, 18 courses of bevacizumab)</arm_group_label>
    <arm_group_label>Arm II (combination chemotherapy, 22 courses of bevacizumab)</arm_group_label>
    <other_name>inhibition therapy, aromatase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the breast with involvement of at least one
             axillary or internal mammary lymph node on routine histologic examination with
             hematoxylin and eosin staining; NOTE: patients with axillary or internal mammary node
             involvement only demonstrated by immunohistochemistry are not eligible

          -  Patients must have completed definitive breast surgery including total mastectomy and
             axillary dissection (modified radical mastectomy), total mastectomy and sentinel node
             biopsy, lumpectomy and axillary dissection, or lumpectomy and sentinel node biopsy;
             NOTE: axillary dissection is strongly encouraged in patients with lymph node
             involvement identified on sentinel node biopsy

          -  Margins of lumpectomy or mastectomy must be histologically free of invasive breast
             cancer and ductal carcinoma in situ (DCIS); patients with resection margins positive
             for lobular carcinoma in situ (LCIS) are eligible

          -  (ARM A ONLY) Interval between last surgery for breast cancer (lumpectomy, mastectomy,
             sentinel node biopsy, axillary dissection or re-excision of lumpectomy margins) and D1
             must be &gt; 28 days and =&lt; 84 days

          -  ECOG performance status of 0-2

          -  Absolute neutrophil count &gt;= 1000/mm^3

          -  Platelet count &gt;= 100,000/mm^3

          -  Total bilirubin =&lt; 1.5 mg/dL

          -  AST =&lt; 2 upper limit of normal

          -  Serum creatinine =&lt; 1.5 mg/dL

          -  Urine protein: creatinine ratio &lt; 1.0

          -  PT INR =&lt; 1.5

          -  PTT =&lt; 1.5 x normal

          -  LVEF &gt;= institutional limits of normal by MUGA or ECHO

          -  Prior to registration the investigator must specify if radiation is planned; patients
             who have undergone a lumpectomy must receive radiation; post-mastectomy radiation is
             at the investigator's discretion

          -  Patients with HER2+ (3+ by IHC or FISH+) breast cancer are not eligible and should be
             treated with a trastuzumab-based adjuvant therapy

          -  Patients with synchronous bilateral breast cancer (diagnosed within one month) are
             eligible if the higher TMN stage tumor meets the eligibility criteria for this trial

          -  Patients must not have clinical evidence of inflammatory disease or fixed axillary
             nodes (N2) at diagnosis

          -  Patients must not have received prior cytotoxic chemotherapy, hormonal therapy or
             radiation for this breast cancer; prior treatment with an anthracycline,
             anthracenedione or taxane for any condition is not allowed; NOTE: prior use of
             tamoxifen for chemoprevention is allowed but must be discontinued at study entry;
             similarly prior raloxifene use is allowed but must be discontinued at study entry

          -  Patients must not have had a major surgical procedure within 4 weeks of entry; NOTE:
             non-operative biopsy or placement of a vascular access device is not considered a
             major surgery

          -  Patients must not have clinically significant cardiovascular disease including:

               -  New York Heart Association (NYHA) grade II or greater congestive heart failure

               -  Grade II or greater peripheral vascular disease

               -  Uncontrolled hypertension defined as SBP &gt; 160 or DBP &gt; 90

               -  Any prior history of cerebrovascular disease including TIA or stroke

          -  Patients must not require therapeutic anticoagulation; patients with a history of deep
             venous thrombosis or pulmonary embolism are not eligible; NOTE: prophylactic use of
             anticoagulants to maintain patency of a vascular assess device is permitted

          -  Patients may not require regular use of aspirin (daily for &gt;= 10 days at doses of &gt;
             325 mg/day) or regular therapeutic doses of other nonsteroidal anti-inflammatory
             agents known to inhibit platelet function; additionally, patients using any of the
             following drugs known to inhibit platelet function are not eligible: dipyridamole
             (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pletal);
             NOTE: regular use of Cox-2 inhibitors is permitted; NOTE: low-dose aspirin is
             permitted

          -  Patients must not have a non-healing wound or fracture; patients with an abdominal
             fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months are
             excluded

          -  Patients must not have hypersensitivity to paclitaxel or drugs using the vehicle
             Cremophor, Chinese hamster ovary cell products or other recombinant human antibodies

          -  Patients who have experienced myocardial infarction or unstable angina within 12
             months are excluded

          -  Patients who have had experienced an arterial thrombotic event within 12 months are
             excluded

          -  Patients must not have uncontrolled or clinical significant arrhythmia

          -  Women must not be pregnant or breast-feeding due to the potential harmful effects of
             bevacizumab on the developing fetus; all females of childbearing potential must have a
             blood test or urine study within 2 weeks prior to registration to rule out pregnancy

          -  Women of childbearing potential and sexually active males are required to use an
             accepted and effective method of contraception while on study and for at least 3-4
             months after the last dose of bevacizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <results_first_submitted>April 4, 2011</results_first_submitted>
  <results_first_submitted_qc>April 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2011</results_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms, Male</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>E2104 was opened on October 6,2005, and closed on November 6, 2006 with the final accrual of 226 patients.Study participants included Eastern Cooperative Oncology Group (ECOG) entire group, North Central Cancer Treatment Group (NCCTG) entire group and Cancer and Leukemia Group B (CALGB) entire group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A (ddBAC &gt; BT &gt; B)</title>
          <description>Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
        </group>
        <group group_id="P2">
          <title>Arm B (ddAC &gt; BT &gt; B)</title>
          <description>Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Treated</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligble</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>others</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A (ddBAC &gt; BT &gt; B)</title>
          <description>Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
        </group>
        <group group_id="B2">
          <title>Arm B (ddAC &gt; BT &gt; B)</title>
          <description>Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="223"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="33" upper_limit="76"/>
                    <measurement group_id="B2" value="50" lower_limit="27" upper_limit="76"/>
                    <measurement group_id="B3" value="50" lower_limit="27" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Congestive Heart Failure Rate</title>
        <description>Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN), or symptomatic diastolic dysfunction. 223 treated patients were included in the analysis.</description>
        <time_frame>assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment, then every 3 months for &lt;2 years and every 6 months for 2-3 years from study entry</time_frame>
        <population>223 treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ddBAC &gt; BT &gt; B)</title>
            <description>Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
          </group>
          <group group_id="O2">
            <title>Arm B (ddAC &gt; BT &gt; B)</title>
            <description>Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Congestive Heart Failure Rate</title>
          <description>Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN), or symptomatic diastolic dysfunction. 223 treated patients were included in the analysis.</description>
          <population>223 treated patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="0.6" upper_limit="8.3"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.5" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Absolute Decrease in Left Ventricular Ejection Fraction (LVEF) Levels Post Doxorubicin and Cyclophosphamide(AC)</title>
        <description>The endpoint was measured by absolute decrease from baseline in LVEF of &gt;15% or &gt;10% decline from baseline to below the LLN post doxorubicin and cyclophosphamide (AC) Day 1 Cycle 5 (DIC5). 207 patients who were treated and had baseline and DIC5 LVEF values were included in the analysis.</description>
        <time_frame>assessed on day 1 of cycles 5, 9, 17, 25, and at end of treatment</time_frame>
        <population>Patients who were treated and had baseline and DIC5 LVEF values</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ddBAC &gt; BT &gt; B)</title>
            <description>Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
          </group>
          <group group_id="O2">
            <title>Arm B (ddAC &gt; BT &gt; B)</title>
            <description>Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Absolute Decrease in Left Ventricular Ejection Fraction (LVEF) Levels Post Doxorubicin and Cyclophosphamide(AC)</title>
          <description>The endpoint was measured by absolute decrease from baseline in LVEF of &gt;15% or &gt;10% decline from baseline to below the LLN post doxorubicin and cyclophosphamide (AC) Day 1 Cycle 5 (DIC5). 207 patients who were treated and had baseline and DIC5 LVEF values were included in the analysis.</description>
          <population>Patients who were treated and had baseline and DIC5 LVEF values</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="3.0" upper_limit="14.7"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0.9" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With Absolute Decrease in LVEF Levels Post Bevacizumab</title>
        <description>The endpoint was measured by absolute decrease from baseline in LVEF of &gt;15% or &gt;10% decline from baseline to below the LLN post bevacizumab (the end of treatment). 158 patients who were treated and had baseline and end of treatment LVEF values were included in the analysis.</description>
        <time_frame>assessed on day 1 of cycles 5, 9, 17, 25, and at end of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm A (ddBAC &gt; BT &gt; B)</title>
            <description>Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
          </group>
          <group group_id="O2">
            <title>Arm B (ddAC &gt; BT &gt; B)</title>
            <description>Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With Absolute Decrease in LVEF Levels Post Bevacizumab</title>
          <description>The endpoint was measured by absolute decrease from baseline in LVEF of &gt;15% or &gt;10% decline from baseline to below the LLN post bevacizumab (the end of treatment). 158 patients who were treated and had baseline and end of treatment LVEF values were included in the analysis.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="7.9" upper_limit="25.7"/>
                    <measurement group_id="O2" value="11.6" lower_limit="5.7" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>assessed at the end of each cycle while on treatment and for 30 days after the end of treatment, and assessed every 3 months if patient is &lt;2 years and every 6 months if patient is 2-3 years from study entry</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A (ddBAC &gt; BT &gt; B)</title>
          <description>Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
        </group>
        <group group_id="E2">
          <title>Arm B (ddAC &gt; BT &gt; B)</title>
          <description>Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac-Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Left ventricular diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom), pharynx</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rectum, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nonneuropathic generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gallbladder, pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection w/gr3-4 neut,lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr3-4 neut, mucosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr3-4 neut, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr0-2 neut, bronchus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr0-2 neut, catheter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr 0-2 neut, lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr 0-2 neut, pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr 0-2 neut, skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr 0-2 neut, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC, mucosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC, oral activity/gums</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC, upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection w/gr 0-2 neut, blood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular assess, Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Joint,pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muscle,pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathic,pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Ocular-other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom), oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom), pharynx</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Oral activity, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Upper GI, hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Abonominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back, pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Extremity-limb,pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Joint,pain</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muscle,pain</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular menses</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nose, hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Chest/thoracic pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nail change</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pruritus/itching</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>Eastern Cooperative Oncology Group (ECOG) Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

